Mingyang Shan
Eli Lilly (United States)(US)Eli Lilly (Singapore)(SG)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Health Systems, Economic Evaluations, Quality of Life, Eosinophilic Esophagitis, Data Quality and Management
Most-Cited Works
- → Factors influencing embodied carbon emissions of China's building sector: An analysis based on extended STIRPAT modeling(2021)122 cited
- → Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults(2022)64 cited
- → Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn’s Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease(2021)37 cited
- → Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn’s Disease: Results from a Global Survey of Patients and Gastroenterologists(2022)34 cited
- → Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis(2022)32 cited
- → Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis(2022)26 cited
- → A New Data Resource to Examine Meals on Wheels Clients’ Health Care Utilization and Costs(2018)23 cited
- → Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study(2021)19 cited
- → Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial(2020)15 cited
- → The impact of symptom severity on the humanistic and economic burden of inflammatory bowel disease: a real-world data linkage study(2022)13 cited